The use of cell-delivered gene therapy for the treatment of HIV/AIDS

Immunologic Research

Volumn 48, Issue 1-3, 2010, Pages 84-98

  Symonds, Geoff P ^a   Johnstone, Helen A ^b   Millington, Michelle L ^a   Boyd, Maureen P ^a   Burke, Bryan P ^a   Breton, Louis R ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Calimmune Australia Inc   (United States)

Author keywords

Cell delivered gene therapy; HIV gene therapy; HIV resistance; HIV AIDS; Short hairpin RNA to CCR5

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; REV PROTEIN; RIBOZYME; SHORT HAIRPIN RNA; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SMALL INTERFERING RNA; TRIPARTITE MOTIF PROTEIN 5; ZINC FINGER PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; CELL BASED GENE THERAPY; CLINICAL TRIAL; ENVELOPE GENE; HEMATOPOIETIC CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; GENE THERAPY; GENES, VIRAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HIV; HIV INFECTIONS; HUMANS; MICE; RECEPTORS, CCR5; RECEPTORS, HIV; RNA, SMALL INTERFERING; VIRUS REPLICATION;

EID: 78549290274     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12026-010-8169-7     Document Type: Review

References (80)

1. www.aidsinfo.nih.gov/Guidelines.
2. ML Robb 2008 Failure of the Merck HIV vaccine: an uncertain step forward Lancet 372 1857 1858 10.1016/S0140-6736(08)61593-7 19012958
3. www.who.int/hiv/data/en/.
4. D Baltimore 1988 Gene therapy. Intracellular immunization Nature 335 395 396 1:STN:280:DyaL1czjsVOitQ%3D%3D 10.1038/335395a0 3166513
5. G Fanning R Amado G Symonds 2003 Gene therapy for HIV/AIDS: the potential for a new therapeutic regimen J Gene Med 5 645 653 1:CAS:528: DC%2BD3sXnvVShtL8%3D 10.1002/jgm.436 12898634 (Pubitemid 40309703)
6. GC Fanning G Symonds 2006 Gene-expressed RNA as a therapeutic: issues to consider, using ribozymes and small hairpin RNA as specific examples Handb Exp Pharmacol 173 289 303 1:CAS:528:DC%2BD28XivVWit7k%3D 10.1007/3-540-27262-3-14 16594621
7. JJ Rossi CH June DB Kohn 2007 Genetic therapies against HIV Nat Biotechnol 25 1444 1454 1:CAS:528:DC%2BD2sXhsVSjurrF 10.1038/nbt1367 18066041 (Pubitemid 350233141)
8. M Giacca 2008 Gene therapy to induce cellular resistance to HIV-1 infection: lessons from clinical trials Adv Pharmacol 56 297 325 1:CAS:528:DC%2BD1cXht1amt78%3D 10.1016/S1054-3589(07)56010-2 18086416
9. J Cohen 2007 Building an HIV-proof immune system Science 317 612 614 1:CAS:528:DC%2BD2sXptVChs7o%3D 10.1126/science.317.5838.612 17673648
10. B Dropulic CH June 2006 Gene-based immunotherapy for human immunodeficiency virus infection and acquired immunodeficiency syndrome Hum Gene Ther 17 577 588 1:CAS:528:DC%2BD28XlvVGmur8%3D 10.1089/hum.2006.17.577 16776567 (Pubitemid 43967862)
11. A Banerjea MJ Li G Bauer L Remling NS Lee J Rossi, et al. 2003 Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages Mol Ther 8 62 71 1:CAS:528:DC%2BD3sXkvFGnur8%3D 10.1016/S1525-0016(03)00140-0 12842429 (Pubitemid 36939297)
12. N Sarver EM Cantin PS Chang JA Zaia PA Ladne DA Stephens, et al. 1990 Ribozymes as potential anti-HIV-1 therapeutic agents Science 247 1222 1225 1:CAS:528:DyaK3cXhslGnur4%3D 10.1126/science.2107573 2107573
13. BC Engel DB Kohn 1999 Stem cell directed gene therapy Front Biosci 4 e26 e33 1:CAS:528:DyaK1MXlt1Whs7s%3D 10.2741/Engel 10228093
14. BL Levine 2008 T lymphocyte engineering ex vivo for cancer and infectious disease Expert Opin Biol Ther 8 475 489 1:CAS:528:DC%2BD1cXjsFWktbk%3D 10.1517/14712598.8.4.475 18352851 (Pubitemid 351570411)
15. BL Levine WB Bernstein NE Aronson K Schlienger J Cotte S Perfetto, et al. 2002 Adoptive transfer of costimulated CD4+ T cells induces expansion of peripheral T cells and decreased CCR5 expression in HIV infection Nat Med 8 47 53 1:CAS:528:DC%2BD38Xjtlygsg%3D%3D 10.1038/nm0102-47 11786906 (Pubitemid 34101728)
16. JL Macpherson MP Boyd AJ Arndt AV Todd GC Fanning JA Ely, et al. 2005 Long-term survival and concomitant gene expression of ribozyme-transduced CD4+ T-lymphocytes in HIV-infected patients J Gene Med 7 552 564 1:CAS:528: DC%2BD2MXltlGjs78%3D 10.1002/jgm.705 15655805 (Pubitemid 40744521)
17. RA Morgan R Walker CS Carter V Natarajan JA Tavel C Bechtel, et al. 2005 Preferential survival of CD4+ T lymphocytes engineered with anti-human immunodeficiency virus (HIV) genes in HIV-infected individuals Hum Gene Ther 16 1065 1074 1:CAS:528:DC%2BD2MXpvVKjtb0%3D 10.1089/hum.2005.16.1065 16149905 (Pubitemid 41324566)
18. I Bahner K Kearns QL Hao EM Smogorzewska DB Kohn 1996 Transduction of human CD34 + hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture J Virol 70 4352 4360 1:CAS:528:DyaK28XjsFygsr4%3D 8676458 (Pubitemid 26187437)
19. RG Amado RT Mitsuyasu JD Rosenblatt FK Ngok A Bakker S Cole, et al. 2004 Anti-human immunodeficiency virus hematopoietic progenitor cell-delivered ribozyme in a phase I study: myeloid and lymphoid reconstitution in human immunodeficiency virus type-1-infected patients Hum Gene Ther 15 251 262 1:CAS:528:DC%2BD2cXhvF2ms7o%3D 10.1089/104303404322886101 15018734 (Pubitemid 38365914)
20. RT Mitsuyasu TC Merigan A Carr JA Zack MA Winters C Workman, et al. 2009 Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells Nat Med 15 285 292 1:CAS:528:DC%2BD1MXhvFKjt74%3D 10.1038/nm.1932 19219022
21. N Cartier S Hacein-Bey-Abina CC Bartholomae G Veres M Schmidt I Kutschera, et al. 2009 Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy Science 326 818 823 1:CAS:528: DC%2BD1MXhtlGhs7zO 10.1126/science.1171242 19892975
22. DB Kohn 2007 Lentiviral vectors ready for prime-time Nat Biotechnol 25 65 66 1:CAS:528:DC%2BD2sXis1Gktg%3D%3D 10.1038/nbt0107-65 17211402 (Pubitemid 46087903)
23. DB Kohn F Candotti 2009 Gene therapy fulfilling its promise N Engl J Med 360 518 521 1:CAS:528:DC%2BD1MXht1Wrtrk%3D 10.1056/NEJMe0809614 19179320
24. A Schambach M Galla T Maetzig R Loew C Baum 2007 Improving transcriptional termination of self-inactivating gamma-retroviral and lentiviral vectors Mol Ther 15 1167 1173 1:CAS:528:DC%2BD2sXhtVejtr%2FP 17406345
25. PY Yam S Li J Wu J Hu JA Zaia JK Yee 2002 Design of HIV vectors for efficient gene delivery into human hematopoietic cells Mol Ther 5 479 484 1:CAS:528:DC%2BD38XislGjtLc%3D 10.1006/mthe.2002.0558 11945076 (Pubitemid 34308674)
26. A Schambach C Baum 2008 Clinical application of lentiviral vectors - concepts and practice Curr Gene Ther 8 474 482 1:CAS:528:DC%2BD1MXhtVSkt70%3D 10.2174/156652308786848049 19075630
27. DS Strayer R Akkina BA Bunnell B Dropulic V Planelles RJ Pomerantz, et al. 2005 Current status of gene therapy strategies to treat HIV/AIDS Mol Ther 11 823 842 1:CAS:528:DC%2BD2MXks1ajs7w%3D 10.1016/j.ymthe.2005.01.020 15922953 (Pubitemid 40724101)
28. J Anderson MJ Li B Palmer L Remling S Li P Yam, et al. 2007 Safety and efficacy of a lentiviral vector containing three anti-HIV genes-CCR5 ribozyme, tat-rev siRNA, and TAR decoy-in SCID-hu mouse-derived T cells Mol Ther 15 1182 1188 1:CAS:528:DC%2BD2sXhtVejtr%2FL 10.1038/sj.mt.6300303 17406343 (Pubitemid 350011743)
29. G Bauer P Valdez K Kearns I Bahner SF Wen JA Zaia, et al. 1997 Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes Blood 89 2259 2267 1:CAS:528:DyaK2sXitVOqurk%3D 9116267
30. P Cordelier JW Kulkowsky C Ko AA Matskevitch HJ McKee JJ Rossi, et al. 2004 Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5 Gene Ther 11 1627 1637 1:CAS:528:DC%2BD2cXovFalsro%3D 10.1038/sj.gt.3302329 15295615 (Pubitemid 39530099)
31. YP Liu B Berkhout 2009 Lentiviral delivery of RNAi effectors against HIV-1 Curr Top Med Chem 9 1130 1143 1:CAS:528:DC%2BD1MXhsFWisbvJ 10.2174/156802609789630866 19860713
32. CD Novina MF Murray DM Dykxhoorn PJ Beresford J Riess SK Lee, et al. 2002 siRNA-directed inhibition of HIV-1 infection Nat Med 8 681 686 1:CAS:528:DC%2BD38XkvFehtro%3D 12042777
33. J Anderson A Banerjea R Akkina 2003 Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance Oligonucleotides 13 303 312 1:CAS:528:DC%2BD3sXpvVektbc%3D 10.1089/ 154545703322616989 15000821 (Pubitemid 38404815)
34. J Bai S Gorantla N Banda L Cagnon J Rossi R Akkina 2000 Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo Mol Ther 1 244 254 1:CAS:528: DC%2BD38XhvF2itbY%3D 10.1006/mthe.2000.0038 10933940
35. XF Qin DS An IS Chen D Baltimore 2003 Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5 Proc Natl Acad Sci USA 100 183 188 1:CAS:528:DC%2BD3sXktlOgtw%3D%3D 10.1073/pnas.232688199 12518064 (Pubitemid 36078049)
36. J Anderson R Akkina 2005 HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector AIDS Res Ther. 2 1 10.1186/1742-6405-2-1 15813990 (Pubitemid 44848757)
37. M Liang M Kamata KN Chen N Pariente DS An IS Chen 2010 Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduction J Gene Med 12 255 265 1:CAS:528:DC%2BC3cXks1Srt7w%3D 10.1002/jgm.1440 20186995
38. Biobusiness Briefs. Trial watch: novel HIV gene therapy enters Phase I trial. Nat Rev Drug Discov. 2009;8:267.
39. EE Perez J Wang JC Miller Y Jouvenot KA Kim O Liu, et al. 2008 Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases Nat Biotechnol 26 808 816 1:CAS:528:DC%2BD1cXot1ent7k%3D 10.1038/nbt1410 18587387 (Pubitemid 351961450)
40. N Holt J Wang K Kim G Friedman X Wang V Taupin 2010 Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo Nat Biotechnol 28 8 839 847 1:CAS:528:DC%2BC3cXotlWktL4%3D 10.1038/nbt.1663 20601939
41. N Zhou J Fang M Mukhtar E Acheampong RJ Pomerantz 2004 Inhibition of HIV-1 fusion with small interfering RNAs targeting the chemokine coreceptor CXCR4 Gene Ther 11 1703 1712 1:CAS:528:DC%2BD2cXpsFahtLo%3D 10.1038/sj.gt. 3302339 15306840 (Pubitemid 39591765)
42. S Basu B Sriram R Goila AC Banerjea 2000 Targeted cleavage of HIV-1 coreceptor-CXCR-4 by RNA-cleaving DNA-enzyme: inhibition of coreceptor function Antiviral Res 46 125 134 1:CAS:528:DC%2BD3cXktVSnurg%3D 10.1016/S0166-3542(00) 00075-9 10854664 (Pubitemid 30347260)
43. J van Lunzen T Glaunsinger I Stahmer V von Baehr C Baum A Schilz, et al. 2007 Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus Mol Ther 15 1024 1033 17356541
44. J Anderson R Akkina 2008 Human immunodeficiency virus type 1 restriction by human-rhesus chimeric tripartite motif 5alpha (TRIM 5alpha) in CD34(+) cell-derived macrophages in vitro and in T cells in vivo in severe combined immunodeficient (SCID-hu) mice transplanted with human fetal tissue Hum Gene Ther 19 217 228 1:CAS:528:DC%2BD1cXjs1ejsLg%3D 10.1089/hum.2007.108 18279037 (Pubitemid 351442727)
45. MR Neagu P Ziegler T Pertel C Strambio-De-Castillia C Grutter G Martinetti, et al. 2009 Potent inhibition of HIV-1 by TRIM5-cyclophilin fusion proteins engineered from human components J Clin Invest 119 3035 3047 1:CAS:528:DC%2BD1MXht1GjurzI 10.1172/JCI39354 19741300
46. IJ Rondon WA Marasco 1997 Intracellular antibodies (intrabodies) for gene therapy of infectious diseases Annu Rev Microbiol 51 257 283 1:CAS:528:DyaK2sXms1ShsbY%3D 10.1146/annurev.micro.51.1.257 9343351 (Pubitemid 27433050)
47. M BouHamdan LX Duan RJ Pomerantz DS Strayer 1999 Inhibition of HIV-1 by an anti-integrase single-chain variable fragment (SFv): delivery by SV40 provides durable protection against HIV-1 and does not require selection Gene Ther 6 660 666 1:CAS:528:DyaK1MXit1Ols70%3D 10.1038/sj.gt.3300864 10476226 (Pubitemid 29192675)
48. J Lisziewicz D Sun J Smythe P Lusso F Lori A Louie, et al. 1993 Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS Proc Natl Acad Sci USA 90 8000 8004 1:CAS:528: DyaK3sXlvFGlsb8%3D 10.1073/pnas.90.17.8000 8367455
49. GA Coburn BR Cullen 2002 Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference J Virol 76 9225 9231 1:CAS:528:DC%2BD38XmslCjt78%3D 10.1128/JVI.76.18.9225-9231.2002 12186906 (Pubitemid 34919881)
50. A Michienzi D Castanotto N Lee S Li JA Zaia JJ Rossi 2003 RNA-mediated inhibition of HIV in a gene therapy setting Ann N Y Acad Sci 1002 63 71 1:CAS:528:DC%2BD2cXisFKhs7w%3D 10.1196/annals.1281.008 14751823 (Pubitemid 38253330)
51. DB Kohn G Bauer CR Rice JC Rothschild DA Carbonaro P Valdez, et al. 1999 A clinical trial of retroviral-mediated transfer of a rev-responsive element decoy gene into CD34(+) cells from the bone marrow of human immunodeficiency virus-1-infected children Blood 94 368 371 1:CAS:528:DyaK1MXktlOksb0%3D 10381536
52. DB Kohn N Sarver 1996 Gene therapy for HIV-1 infection Adv Exp Med Biol 394 421 428 1:CAS:528:DyaK28XktF2hurw%3D 8815708
53. I Bahner T Sumiyoshi M Kagoda R Swartout D Peterson K Pepper, et al. 2007 Lentiviral vector transduction of a dominant-negative Rev gene into human CD34+ hematopoietic progenitor cells potently inhibits human immunodeficiency virus-1 replication Mol Ther 15 76 85 1:CAS:528:DC%2BD2sXhtVejurbP 10.1038/sj.mt. 6300025 17164778 (Pubitemid 46043652)
54. S Todd C Anderson DJ Jolly CS Craik 2000 HIV protease as a target for retrovirus vector-mediated gene therapy Biochim Biophys Acta 1477 168 188 1:CAS:528:DC%2BD3cXhsFGktLc%3D 10708857
55. M Ishaq J Hu X Wu Q Fu Y Yang Q Liu, et al. 2008 Knockdown of cellular RNA helicase DDX3 by short hairpin RNAs suppresses HIV-1 viral replication without inducing apoptosis Mol Biotechnol 39 231 238 1:CAS:528: DC%2BD1cXntVWitrw%3D 10.1007/s12033-008-9040-0 18259889
56. LM Humeau GK Binder X Lu V Slepushkin R Merling P Echeagaray, et al. 2004 Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load Mol Ther 9 902 913 1:CAS:528:DC%2BD2cXkvVegs7w%3D 10.1016/j.ymthe.2004.03.005 15194057 (Pubitemid 38878136)
57. D von Laer S Hasselmann K Hasselmann 2006 Gene therapy for HIV infection: what does it need to make it work? J Gene Med 8 658 667 10.1002/jgm.908
58. DS An RE Donahue M Kamata B Poon M Metzger SH Mao, et al. 2007 Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates Proc Natl Acad Sci USA 104 13110 13115 1:CAS:528: DC%2BD2sXpt1Gguro%3D 10.1073/pnas.0705474104 17670939 (Pubitemid 351737601)
59. S Shimizu P Hong B Arumugam L Pokomo J Boyer N Koizumi, et al. 2010 A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model Blood 115 1534 1544 1:CAS:528:DC%2BC3cXjtV2gt7k%3D 10.1182/blood-2009-04-215855 20018916
60. S Shimizu M Kamata P Kittipongdaja KN Chen S Kim S Pang, et al. 2009 Characterization of a potent non-cytotoxic shRNA directed to the HIV-1 co-receptor CCR5 Genet Vaccines Ther. 7 8 10.1186/1479-0556-7-8 19515239
61. DS An FX Qin VC Auyeung SH Mao SK Kung D Baltimore, et al. 2006 Optimization and functional effects of stable short hairpin RNA expression in primary human lymphocytes via lentiviral vectors Mol Ther 14 494 504 1:CAS:528:DC%2BD28XptFCgsb0%3D 10.1016/j.ymthe.2006.05.015 16844419 (Pubitemid 44339392)
62. G Hutter D Nowak M Mossner S Ganepola A Mussig K Allers, et al. 2009 Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation N Engl J Med 360 692 698 10.1056/NEJMoa0802905 19213682
63. P Dorr M Westby S Dobbs P Griffin B Irvine M Macartney, et al. 2005 Maraviroc (UK-427, 857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity Antimicrob Agents Chemother 49 4721 4732 1:CAS:528:DC%2BD2MXht1Siu7rM 10.1128/AAC.49.11.4721-4732.2005 16251317 (Pubitemid 41552605)
64. P Pugach AJ Marozsan TJ Ketas EL Landes JP Moore SE Kuhmann 2007 HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry Virology 361 212 228 1:CAS:528:DC%2BD2sXkt1ajt7g%3D 10.1016/j.virol.2006.11.004 17166540 (Pubitemid 46551222)
65. M Westby C Smith-Burchnell J Mori M Lewis M Mosley M Stockdale, et al. 2007 Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry J Virol 81 2359 2371 1:CAS:528: DC%2BD2sXitVOgs70%3D 10.1128/JVI.02006-06 17182681
66. C Woffendin U Ranga Z Yang L Xu GJ Nabel 1996 Expression of a protective gene-prolongs survival of T cells in human immunodeficiency virus-infected patients Proc Natl Acad Sci USA 93 2889 2894 1:CAS:528:DyaK28XitVCit7o%3D 10.1073/pnas.93.7.2889 8610137 (Pubitemid 26116244)
67. U Ranga C Woffendin S Verma L Xu CH June DK Bishop, et al. 1998 Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals Proc Natl Acad Sci USA 95 1201 1206 1:CAS:528:DyaK1cXosFSqsA%3D%3D 10.1073/pnas.95.3.1201 9448309 (Pubitemid 28124936)
68. GM Podsakoff BC Engel DA Carbonaro C Choi EM Smogorzewska G Bauer, et al. 2005 Selective survival of peripheral blood lymphocytes in children with HIV-1 following delivery of an anti-HIV gene to bone marrow CD34(+) cells Mol Ther 12 77 86 1:CAS:528:DC%2BD2MXlt1GlsL4%3D 10.1016/j.ymthe.2005.02.024 15963923 (Pubitemid 40862359)
69. G Bauer D Selander B Engel D Carbonaro S Csik S Rawlings, et al. 2000 Gene therapy for pediatric AIDS Ann N Y Acad Sci 918 318 329 1:CAS:528:DC%2BD3MXhsVej 10.1111/j.1749-6632.2000.tb05501.x 11131719
70. BL Levine LM Humeau J Boyer RR MacGregor T Rebello X Lu, et al. 2006 Gene transfer in humans using a conditionally replicating lentiviral vector Proc Natl Acad Sci USA 103 17372 17377 1:CAS:528:DC%2BD28Xht1KqsbjM 10.1073/pnas.0608138103 17090675 (Pubitemid 44788976)
71. Tebas P, Stein D, Zifchak L, Seda A, Binder G, Aberra F et al. Prolonged control of viremia after transfer of autologous CD4 T cells genetically modified with a lentiviral vector expressing long antisense to HIV env. 17th Conference on retroviruses and opportunistic infections paper #388 accessed at http://www.retroconference.org/2010/Abstracts/39297.htm.
72. Kreeger K. Phase II HIV gene therapy trial data at CROI 2010 presented by Penn Researchers: 19 Feb 2010. Accessed at http://www.medicalnewstoday.com/ articles/179756.php.
73. F Wong-Staal EM Poeschla DJ Looney 1998 A controlled, Phase 1 clinical trial to evaluate the safety and effects in HIV-1 infected humans of autologous lymphocytes transduced with a ribozyme that cleaves HIV-1 RNA Hum Gene Ther 9 2407 2425 1:CAS:528:DyaK1cXntlelsrc%3D 10.1089/hum.1998.9.16-2407 9829540
74. RG Amado RT Mitsuyasu G Symonds JD Rosenblatt J Zack LQ Sun, et al. 1999 A phase I trial of autologous CD34+ hematopoietic progenitor cells transduced with an anti-HIV ribozyme Hum Gene Ther 10 2255 2270 1:STN:280: DyaK1Mvis1Gntg%3D%3D 10.1089/10430349950017239 10498256 (Pubitemid 29416304)
75. DL DiGiusto A Krishnan L Li H Li S Li A Rao, et al. 2010 RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma Sci Transl Med 2 36 43
76. Sangamo Biosciences Press Release: Sangamo Biosciences intiates phase 1 trial of CCR5-ZFP therapeutic to treat HIV/AIDS. 03 Feb, 2009 accessed at http://investor.sangamo.com/releasedetail.cfm?ReleaseID=363201.
77. Sangamo Biosciences Press Release: Sangamo Biosciences announces plans to initiate a second clinical trial of CCR5-ZFP therapeutic to treat HIV/AIDS. 23 Sept, 2009 accessed at http://investor.sangamo.com/releasedetail.cfm?ReleaseID= 410950.
78. Sangamo Biosciences Press Release: Sangamo Biosciences announces presentation of preliminary data from phase 1 safety trial of SB-728-T for HIV/AIDS. 19 Jan, 2010 accessed at http://investor.sangamo.com/releasedetail. cfm?ReleaseID=438350.
79. RT Mitsuyasu PA Anton SG Deeks DT Scadden E Connick MT Downs, et al. 2000 Prolonged survival and tissue trafficking following adoptive transfer of CD4zeta gene-modified autologous CD4(+) and CD8(+) T cells in human immunodeficiency virus-infected subjects Blood 96 785 793 1:CAS:528: DC%2BD3cXltlKitrw%3D 10910888
80. SG Deeks B Wagner PA Anton RT Mitsuyasu DT Scadden C Huang, et al. 2002 A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy Mol Ther 5 788 797 1:CAS:528:DC%2BD38XktFGjuro%3D 10.1006/mthe.2002.0611 12027564 (Pubitemid 34619072)